Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo

Cancer Biology and Therapy

Volumn 7, Issue 4, 2008, Pages 587-593

  Hamed, Hossein ^a   Mitchell, Clint ^a   Park, Margaret A ^a   Hanna, David ^a   Martin, Aditi Pandya ^a   Harrison, Benjamin ^a   Hawkins, William ^a   Curiel, David A ^d   Fisher, Paul B ^a   Grant, Steven ^b   Yacoub, Adly ^a,c   Hagan, Michael P ^c   Dent, Paul ^a,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cell death; hCG; Lovastatin; Radiation

Indexed keywords

CHORIONIC GONADOTROPIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KI 67 ANTIGEN; MEVINOLIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; IONIZING RADIATION; MOUSE; NONHUMAN; PROSTATE CANCER;

EID: 45349085110     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.4.5543     Document Type: Article

References (41)

1. Hong SH, Ji IH, Ji TH. The beta-subunit of human choriogonadotropin interacts with the exodomain of the luteinizing hormone/choriogonadotropin receptor and changes its interaction with the alpha-subunit. Mol Endocrinol 1999; 13:1285-94.
2. Filicori M, Fazleabas AT, Huhtaniemi I, Licht P, Rao ChV, Tesarik J, Zygmunt M. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril 2005; 84:275-84.
3. Styne DM. Puberty and its disorders in boys. Endocrinol Metab Clin North Am 1991; 20:43-69.
4. Sheaff MT, Martin JE, Badenoch DF, Baithun SI. beta hCG as a prognostic marker in adenocarcinoma of the prostate. J Clin Pathol 1996; 49:329-32.
5. Huhtaniemi I, Rulli S, Ahtiainen P, Poutanen M. Multiple sites of tumorigenesis in transgenic mice overproducing hCG. Mol Cell Endocrinol 2005; 234:117-26.
6. Cole LA, Dai D, Butler SA, Leslie KK, Kohorn EI. Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG. Gynecol Oncol 2006; 102:145-50.
7. Salhab M, Al Sarakbi W, Mokbel K. In vitro fertilization and breast cancer risk: a review. Int J Fertil Womens Med 2005; 50:259-66.
8. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7:472-9.
9. Collette L, Burzykowski T, Schroder FH. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006; 42:1344-50.
10. Ryan CJ, Small EJ. Advances in prostate cancer. Curr Opin Oncol 2004; 16:242-6.
11. Flores E, Bratoeff E, Cabeza M, Ramirez E, Quiroz A, Heuze I. Steroid 5alpha-reductase inhibitors. Mini Rev Med Chem 2003; 3:225-37.
12. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22:2954-63.
13. Roberts CT Jr. IGF-1 and prostate cancer. Novartis Found Symp 2004; 262:193-9.
14. Barton J, Blackledge G, Wakeling A. Growth factors and their receptors: new targets for prostate cancer therapy. Urology 2001; 58:114-22.
15. Formento P, Hannoun-Levi JM, Fischel JL, Magne N, Etienne-Grimaldi MC, Milano G. Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab. Eur J Cancer 2004; 40:2837-44.
16. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. MAPK pathways in radiation responses. Oncogene 2003; 22:5885-96.
17. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S, Schmidt-Ullrich R. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 2003; 159:283-300.
18. Pond-Tor S, Rhodes RG, Dahlberg PE, Leith JT, McMichael J, Dahlberg AE. Enhancement of radiosensitivity of the MCF-7 breast cancer cell line with human chorionic gonadotropin. Breast Cancer Res Treat 2002; 72:45-51.
19. Yacoub A, Hawkins W, Hanna D, Young H, Park MA, Grant M, Roberts JD, Curiel DT, Fisher PB, Valerie K, Grant S, Hagan MP, Dent P. Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment. Mol Pharmacol 2007; 71:259-75.
20. Hagan MP, Yacoub A, Dent P.Radiation-induced PARP activation is enhanced through EGFR-ERK signaling. J Cell Biochem 2007; 101:1384-93.
21. Hagan M, Yacoub A, Dent P. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Clin Cancer Res 2004; 10:5724-31.
22. Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biol Ther 2005; 4:1275-84.
23. Yacoub A, Gilfor D, Hawkins W, Park MA, Hanna D, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P.MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo. Cancer Biol Ther 2006; 5:1332-9.
24. Caron RW, Yacoub A, Li M, Zhu X, Mitchell C, Hong Y, Hawkins W, Sasazuki T, Shirasawa S, Kozikowski AP, Dennis PA, Hagan MP, Grant S, Dent P. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1 and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther 2005; 4:257-70.
25. Caron RW, Yacoub A, Zhu X, Mitchell C, Han SI, Sasazuki T, Shirasawa S, Hagan MP, Grant S, Dent P. H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. Mol Cancer Ther 2005; 4:243-55.
26. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999; 10:2493-506.
27. Soliman AT, Nasr I, Thabet A, Rizk MM, El Matary W. Human chorionic gonadotropin therapy in adolescent boys with constitutional delayed puberty vs those with beta-thalassemia major. Metabolism 2005; 54:15-23.
28. Delemarre-van de Waal HA. Application of gonadotropin releasing hormone in hypogonadotropic hypogonadism - diagnostic and therapeutic aspects. Eur J Endocrinol 2004; 151:89-94.
29. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sorensen HT, Olsen JH. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114:643-7.
30. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004; 22:2388-94.
31. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Asano T, Hayakawa M. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 2004; 10:8648-55.
32. Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, Adamovich E. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005; 66:1150-4.
33. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study. Cancer Epidemiol Biomarkers Prev 2007; 16:2226-32.
34. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, Orav EJ, Seeger JD, Sadler MC, Quesenberry CP Jr, Sternfeld B, Jacobsen SJ, Whitmer RA, Caan BJ.Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16:2218-25.
35. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large u.s. Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16:2213-7.
36. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2:483-90.
37. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004; 64:6461-8.
38. Lauve AD, Siebers JV, Crimaldi AJ, Hagan MP, Keall PJ.A dynamic compensation strategy to correct patient-positioning errors in conformal prostate radiotherapy. Med Phys 2006; 33:1879-87.
39. Gordon JJ, Crimaldi AJ, Hagan M, Moore J, Siebers JV. Evaluation of clinical margins via simulation of patient setup errors in prostate IMRT treatment plans. Med Phys 2007; 34:202-14.
40. De Meerleer G, Vakaet L, Meersschout S, Villeirs G, Verbaeys A, Oosterlinck W, De Neve W. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 2004; 60:777-87.
41. Morton GC. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol) 2005; 17:219-27.